AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03657212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
Study NCT03657212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Description: The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
Study NCT01709214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol (GRT6005) Low-Dose Range
Description: Capsules
Study NCT01709214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol (GRT6005) High-Dose Range
Description: Capsules
Study NCT01709214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Study NCT02158234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 15 mg/m\^2 prior to each fraction
Study NCT01709214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Study NCT01709214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: Capsules containing oxycodone CR 10 or 20 milligrams
Study NCT00418210 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
Description: Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
Study NCT02403713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol BAI
Description: Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
Study NCT02403713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol
Study NCT02403713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI without spacer
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer
Study NCT02403713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI with spacer
Description: Fluticasone/Formoteral 125/5µg pMDI with spacer
Study NCT02403713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/formoterol PMDI without spacer low dose
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
Study NCT03239886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imatinib discontinuation
Description: imatinib discontinuation
Study NCT03326609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
Study NCT04282070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Study NCT04282070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study NCT04282070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT04282070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Maximum 6 cycles for combined therapy.
Study NCT01753388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liberty Stent
Study NCT03281447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse navigation
Study NCT03281447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care coordination
Study NCT02690324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive stress (serial 7)
Study NCT02690324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive stress (serial 7)
Study NCT01989754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily for 156 weeks
Study NCT01989754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily
Study NCT01989754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study NCT04212052 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
Study NCT04212052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
Study NCT04212052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation immunotherapy
Description: Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
Study NCT02268448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT02158234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
Study NCT02201238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: Diclofenac sodium
Study NCT02201238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac sodium
Study NCT03363958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning with Postconditioning
Description: Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
Study NCT03363958 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC procedure
Description: Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
Study NCT04444388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa
Description: Sachets of 5 grams of cocoa daily supplementation
Study NCT02268448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT01338935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1).
Study NCT01338935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study.
Study NCT01338935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.
Study NCT01183312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Sublingual flumazenil
Study NCT00201981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: 1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
Study NCT01388868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOF count guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
Study NCT01388868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1/ T0 guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
Study NCT01388868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2/ T0 guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
Study NCT03046160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (Mobilization with movement)
Description: grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
Study NCT04444388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets of 5 grams of maltodextrin daily supplementation
Study NCT03678051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+CBT4CBT
Description: 45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
Study NCT03046160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck and scapular exercises.
Description: A program of 12 neck and scapular exercises.
Study NCT03046160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neck and scapular exercises.
Description: A program of 12 neck and scapular exercises.
Study NCT04232943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine (IPV)
Description: IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units
Study NCT04232943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (IPV)
Description: IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units
Study NCT04232943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)
Description: LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules.
Study NCT04232943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3.
Study NCT04232943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3.
Study NCT06004206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nPSV and PSV
Description: Ventilation with neurally adjusted modes or pressure support modes
Study NCT03420937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
Study NCT03420937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine, Atropin Biotika
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
Study NCT02955238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum.
Study NCT02964806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ordinary Diet
Study NCT02964806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Modified Atkin's Diet
Study NCT02964806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketogenic Diet
Study NCT03971175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps biopsy
Description: Endobronchial biopsy with the forceps
Study NCT03971175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Endobronchial biopsy with the cryobiopsy probe
Study NCT02575443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (MB group)
Description: Count of train-of-four: 1-2 Titration of rocuronium dose
Study NCT02575443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (DB group)
Description: Post-tetanic count: 1-2 Titration of rocuronium dose
Study NCT04231097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBCT intervention for ACS patients
Description: The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
Study NCT01773954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: Increased or decreased time between visits
Study NCT00507585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
Study NCT00507585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
Study NCT03046160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corrective tape
Description: elastic tape used to correct the anterior tilt of the scapula
Study NCT02201238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Menthol
Study NCT03046160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective tape
Description: elastic tape used to correct the anterior tilt of the scapula
Study NCT02044796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT00507585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
Study NCT01985334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
Study NCT02044796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02044796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02044796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02044796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT00063635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg, twice daily
Study NCT00063635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: 400 IU, twice daily
Study NCT00063635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Twice daily
Study NCT04067427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental training
Description: App-based mental training